HomeInsightsStock Comparison

Biocon Ltd vs Wockhardt Ltd Stock Comparison

Biocon Ltd vs Wockhardt Ltd Stock Comparison

Last Updated on: Aug 02, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 382.95 as of 01 Aug 15:30.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 40.4 on March 2025 . This represents a CAGR of -1.19% over 6 yearsThe P/E Ratio of Wockhardt Ltd changed from 6.6 on March 2021 to 0 on March 2025 . This represents a CAGR of -100.00% over 5 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 40964 crore on March 2025 . This represents a CAGR of 3.95% over 6 yearsThe Market Cap of Wockhardt Ltd changed from ₹ 1912 crore on March 2020 to ₹ 23133 crore on March 2025 . This represents a CAGR of 51.50% over 6 years.
  • The revenue of Biocon Ltd for the Mar '25 is ₹ 4474 crore as compare to the Dec '24 revenue of ₹ 3874 crore. This represent the growth of 15.49% The revenue of Wockhardt Ltd for the Mar '25 is ₹ 758 crore as compare to the Dec '24 revenue of ₹ 729 crore. This represent the growth of 3.98%.
  • The ebitda of Biocon Ltd for the Mar '25 is ₹ 1135 crore as compare to the Dec '24 ebitda of ₹ 804.7 crore. This represent the growth of 41.11% The ebitda of Wockhardt Ltd for the Mar '25 is ₹ 79 crore as compare to the Dec '24 ebitda of ₹ 136 crore. This represent the decline of -41.91%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 459.4 crore over 8 quarters. This represents a CAGR of 75.65% The net profit of Wockhardt Ltd changed from ₹ -136 crore to ₹ -45 crore over 8 quarters. This represents a CAGR of -42.48% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 9.85 % on March 2025 . This represents a CAGR of -38.69% over 4 yearsThe Dividend Payout of Wockhardt Ltd changed from 0 % on March 2020 to 0 % on March 2025 . This represents a CAGR of 0.0% over 6 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Wockhardt Ltd

  • Wockhardt Limited, incorporated in July, 1999 is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world.
  • The Company is India's leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals.
  • It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out. The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland.
  • It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses.
  • Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable 'Superbugs'.

Biocon Ltd News Hub

News

Biocon edges higher after biologics arm launches autoimmune treatment drug Nepexto in Australia

Nepexto will be promoted by Generic Health, BBL's local partner and a leading provider of ...

Read more

23 Jul 2025 10:33

News

Biocon arm gets USFDA approval for insulin, Kirsty

Kirsty is biosimiler to Novolog. It is a rapid-acting human insulin analog indicated to im...

Read more

16 Jul 2025 08:32

News

Biocon Ltd gains for third straight session

Biocon Ltd gained for a third straight session today. The stock is quoting at Rs 390, up 2...

Read more

15 Jul 2025 13:05

News

Biocon schedules board meeting

Biocon will hold a meeting of the Board of Directors of the Company on 7 August 2025. Powe...

Read more

09 Jul 2025 10:55

News

Biocon gets MHRA UK approval for marketing Denosumab biosimilars 'Vevzuo' & 'Evfraxy'

Vevzuo is authorized for the prevention of skeletal related events (pathological fracture,...

Read more

07 Jul 2025 10:27

News

Biocon's biologics arm gets regulatory approval in EU for Denosumab biosimilars

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (...

Read more

03 Jul 2025 09:50

Wockhardt Ltd News Hub

News

Wockhardt's proprietary antibiotic Zaynich' gets mentioned in leading U.K. Medical Journal

A clinically challenging case involving Wockhardt's novel antibiotic Zaynich' was recently...

Read more

28 Jul 2025 09:03

News

Wockhardt to hold AGM

Wockhardt announced that the 26th Annual General Meeting(AGM) of the company will be held ...

Read more

17 Jul 2025 16:03

News

Wockhardt climbs on exiting US generics to refocus on innovation

The move is aimed at realigning focus toward high-impact areas, including novel antibiotic...

Read more

14 Jul 2025 17:12

News

Wockhardt undertakes realignment of its US business

Wockhardt is undertaking significant strategic realignment of its US business in line with...

Read more

11 Jul 2025 16:28

News

Wockhardt to conduct board meeting

Wockhardt will hold a meeting of the Board of Directors of the Company on 29 May 2025. Pow...

Read more

24 May 2025 18:26

News

Wockhardt announces incorporation of step-down subsidiary in Ireland

Wockhardt Bio AG, a subsidiary of Wockhardt, has incorporated a new Wholly Owned Subsidiar...

Read more

08 Apr 2025 19:55

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Wockhardt Ltd

Strength

3

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Wockhardt Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Wockhardt Ltd

Which company has a larger market capitalization, Biocon Ltd or Wockhardt Ltd?

Market cap of Biocon Ltd is 51,199 Cr while Market cap of Wockhardt Ltd is 26,166 Cr

What are the key factors driving the stock performance of Biocon Ltd and Wockhardt Ltd?

The stock performance of Biocon Ltd and Wockhardt Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Wockhardt Ltd?

As of August 2, 2025, the Biocon Ltd stock price is INR ₹382.95. On the other hand, Wockhardt Ltd stock price is INR ₹1610.4.

How do dividend payouts of Biocon Ltd and Wockhardt Ltd compare?

To compare the dividend payouts of Biocon Ltd and Wockhardt Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions